Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose selection study of RP 01 anti-IgE immunotherapy in allergic patients
2007-006551-39Phase 2Terminated
- Sponsor
- Resistentia Pharmaceuticals
- Start
- Dec 2007
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RP01 in allergy (3 arms), sponsored by Resistentia Pharmaceuticals. Primary endpoints: Maximum tolerable effective dose of RP 01, Specific immune response markers (IgG anti-IgE and IgG anti-OSO) and 2 more. Started Dec 2007; status: terminated.
02
Drugs
RP01
03
Conditions
allergy
Beyond the preview
Go deeper on 2007-006551-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006551-39.